Deep Dermal Bioremodeling: How Polynucleotides (PN/PDRN) Activate A2A Receptors to Repair Atrophic Tissue

In aesthetic medicine, treating severe dermal atrophy, deep crepey skin, and compromised tissue repair presents a unique challenge. Traditional crosslinked hyaluronic acid (HA) fillers excel at replacing lost volume, but placing volumetric gels into thin, structurally depleted skin can result in over-projection, surface unnaturalness, or the Tyndall effect.

Rather than merely expanding tissue space with volumetric fillers, regenerative aesthetic medicine focuses on physiological bioremodeling—reprogramming the extracellular matrix (ECM) to heal and re-densify itself from within.

Leading this shift toward true cellular regeneration are Polynucleotides (PN) and Polydeoxyribonucleotides (PDRN). Derived from purified salmon DNA fragments, these biopolymers act as direct physiological signals that bind adenosine A2A cell-surface receptors, triggering native collagen synthesis, wound repair, and long-term tissue restoration, and are actively being invested in by preimum biotech organizations like Ninaveli, Allergan Aesthetics, and Medytox.

1. The Cellular Deficit: Dermal Atrophy and Matrix Collapse

Dermal atrophy occurs when the rate of extracellular matrix breakdown outpaces the synthetic capacity of local fibroblasts. Driven by intrinsic aging, chronic UV exposure, and hormonal shifts:

Fibroblast Hypo-Activity: Aging fibroblasts lose their mechanical stretching attachments to surrounding collagen, entering a state of reduced metabolic activity with diminished synthesis of Type I collagen and endogenous hyaluronan.
Micro-Vascular Ischemia: Capillary density in the papillary dermis declines, reducing oxygen and nutrient delivery to basal keratinocytes and dermal cells.
Persistent Micro-Inflammation: Low-grade inflammatory cytokines maintain elevated matrix metalloproteinase (MMP) levels, continuously breaking down the structural scaffold.

Simply hydrating this depleted environment with non-crosslinked HA provides temporary moisture, but it fails to provide the biological signals needed to rebuild damaged dermal architecture.

2. The Dual Bioremodeling Mechanism: Polynucleotides (PN/PDRN)

Polynucleotides are high-molecular-weight DNA polymers composed of purine and pyrimidine nucleotide chains. When introduced into the dermis via intradermal micro-injections or transdermal micro-channeling, they operate through two distinct pathways:

A. Adenosine A2A Receptor Activation

The primary therapeutic driver of PN/PDRN is its ability to selectively bind to adenosine A2A cell-surface receptors on dermal fibroblasts, endothelial cells, and immune cells:

Fibroblast Stimulation: A2A receptor binding activates intracellular adenylate cyclase, elevating cAMP levels and upregulating the expression of Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF). This signals dormant fibroblasts to proliferate and synthesize fresh Type I collagen and elastin fibers.
Anti-Inflammatory Modulation: A2A activation suppresses pro-inflammatory cytokines (such as TNF-alpha, IL-6, and HMGB1) while upregulating anti-inflammatory IL-10, creating an ideal microenvironment for tissue regeneration.

B. The Nucleoside “Salvage Pathway” & Isotonic Hydration

As endonucleases gradually cleave the long DNA polymers of PN/PDRN into smaller nucleosides and nucleotides, these free bases are reabsorbed by local cells via the purine salvage pathway. This provides ready-made building blocks for cellular DNA repair and synthesis, saving metabolic energy during tissue recovery.

Simultaneously, the polymeric structure of PN binds large amounts of water molecules, providing immediate viscoelastic hydration and isometric cushioning to thin, creping skin.

3. Clinical Evidence: What the Science Confirms

1. Selective A2A Receptor Binding and Collagen Synthesis

In a comprehensive pharmacological study published in Pharmaceuticals (MDPI), “PDRN: A Bio-Rejuvenating Agent for Tissue Repair and Regeneration,” researchers evaluated the molecular pathways driven by polydeoxyribonucleotides.

The objective data confirmed that PDRN specifically binds A2A receptors, triggering a statistically significant upregulation of collagen Type I deposition, VEGF expression, and capillary neovascularization in damaged dermal models. The researchers noted that blocking the A2A receptor completely eliminated PDRN’s regenerative effects, proving its receptor-mediated mechanism.

2. Clinical Improvement in Skin Elasticity and Dermal Thickness

In a clinical evaluation published in PMC, “Polynucleotides in Aesthetic Medicine: A Systematic Review of Clinical Efficacy,” investigators tracked subjects receiving intradermal PN/PDRN injections for facial atrophy and periorbital creping.

High-frequency ultrasound imaging and profilometry demonstrated a statistically significant increase in dermal thickness and skin elasticity after 3 to 4 treatment sessions. Clinical evaluators confirmed significant smoothing of fine lines and improved tissue firmness without palpable nodules, vascular compromise, or artificial volume distortion.

4. Practice Summary

Polynucleotides (PN/PDRN) offer an effective regenerative solution for addressing structural skin atrophy. By selectively binding adenosine A2A receptors, supplying essential nucleosides via the salvage pathway, and providing viscoelastic hydration, PN/PDRN protocols trigger natural tissue remodeling. This allows aesthetic practitioners to repair thin, damaged skin, boost native collagen density, and restore youthful tissue elasticity.

Study Citations & References

Study 1 (PDRN A2A Receptor Mechanisms & Repair): PDRN: A Bio-Rejuvenating Agent for Tissue Repair and Regeneration.URL: https://www.mdpi.com/1424-8247/14/11/1103
Study 2 (Polynucleotides Systematic Review in Aesthetics): Polynucleotides in Aesthetic Medicine: A Systematic Review.URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8983239/
Study 3 (Nucleoside Salvage Pathway in Dermal Fibroblasts): The Role of Adenosine A2A Receptor Agonists in Skin Wound Healing.URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7607370/

Frequently Asked Questions

How do Polynucleotides (PN/PDRN) differ from traditional Hyaluronic Acid (HA) dermal fillers?

Traditional crosslinked Hyaluronic Acid fillers are volumetric gels designed to physically push up tissue and fill deep folds or restore lost facial fat pads.
Polynucleotides (PN/PDRN) are biological signaling molecules derived from purified DNA fragments. They do not act as physical space-occupying fillers; instead, they bind to adenosine A2A receptors on fibroblasts to signal the skin to produce its own new collagen, elastin, and hyaluronan. They re-densify thin, crepey skin from within without adding artificial volume.

Can Polynucleotides be combined with other aesthetic procedures like microneedling or HA skin boosters?

Yes, Polynucleotides pair exceptionally well with biostimulatory treatments. Combining PN/PDRN with microneedling or micro-channeling creates ideal pathways for deep dermal absorption, accelerating the wound-healing cascade.

Additionally, combining PN/PDRN with non-crosslinked Hyaluronic Acid (HA skin boosters) creates a synergistic effect: the HA provides immediate surface hydration, while the Polynucleotides stimulate long-term cellular repair and matrix re-densification.

How many sessions are required, and when do patients notice results with PN/PDRN treatments?

Because Polynucleotides rely on cellular regeneration and collagen synthesis, results build progressively over time. Initial improvements in tissue hydration and skin softness are often visible within 10 to 14 days post-treatment.
For optimal structural remodeling and dermal re-densification, a standard clinical protocol consists of 3 to 4 sessions spaced 2 to 3 weeks apart. Maximum collagen density and tissue elasticity improvements typically peak at 2 to 3 months following the full regimen.

Disclaimer: The content provided in the Ninaveli Knowledge Hub is for informational and educational purposes only. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment and should not be used as such. Always seek the advice of a qualified healthcare provider or dermatologist with any questions you may have regarding a medical condition or before starting any new skincare regimen. Ninaveli does not guarantee the accuracy, completeness, or timeliness of the information provided and assumes no liability for any actions taken based on this content.